REMS PATIENT SAFETY

Welcome to the REMS Programs Administered by Bristol Myers Squibb

To avoid embryo-fetal exposure, Risk Evaluation and Mitigation Strategy (REMS) programs are mandatory for the REMS products THALOMID® (thalidomide), POMALYST® (pomalidomide), REVLIMID® (lenalidomide) and generic lenalidomide. The THALOMID REMS® program, Lenalidomide REMS program and POMALYST REMS® program require prescribers and pharmacists to be certified and patients to enroll and comply with all of the requirements for each program.

If you would like to obtain more information about any of the Bristol Myers Squibb-administered REMS programs, please click on the program name below:

Visit
www.LenalidomideREMS.com, to learn more about the Lenalidomide REMS program.

Visit
www.POMALYSTREMS.com, to learn more about the POMALYST REMS® program.

Visit
www.THALOMIDREMS.com, to learn more about the THALOMID REMS® program.

To complete a REMS related task, please select the appropriate option from below:

Prescribers: The Prescriber Portal for Bristol Myers Squibb-administered REMS Programs can be accessed by clicking on the below button. Please enter your User Name and Password to manage your patients. If you do not have an online account, select Create User Account to establish an account.

Patients: Patients currently enrolled in a Bristol Myers Squibb-administered REMS program are not required to create an online account to complete a survey. Please select Patient Surveys and enter the information requested to begin a survey.

Pharmacies: The Pharmacy Portal for Bristol Myers Squibb-administered REMS Programs can be accessed by clicking on the below button. Please enter your Username and Password to begin. If you do not have an online account, please contact your REMS Representative.